Table 4.

Acute mTOR inhibition does not eliminate AGS in the Fmr1 KO

IncidenceWild runningClonicTonicDeath
KO vehicle63%10/169/165/161/16
KO rapamycin33%6/181/181/180/18
WT vehicle0%*0/160/160/160/16
WT rapamycin0%*0/150/150/150/15
  • Fmr1 KO and WT mice were injected with 6 mg/kg rapamycin or vehicle (100% DMSO). After 1 h, mice were exposed to a seizure-inducing stimulus for 2 min, and scored for wild running, clonic seizure, tonic seizure, and death. Results reveal that treatment with rapamycin does not significantly reduce the incidence of AGS in Fmr1 KO mice (Fisher's exact test; KO control versus WT control, *p < 0.005; KO control versus KO rapamycin, p = 0.372; KO control versus WT rapamycin, *p < 0.005). A slight decrease in AGS incidence was observed in this cohort of vehicle-treated Fmr1 KO mice (cf. Table 3), which we ascribe to the higher concentration of DMSO required to solubilize rapamycin and ensure proper absorption.